← All trials
NCT03454451
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 25, 2018
- Primary completion
- Mar 31, 2022
- Completion date
- Dec 31, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 378
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Corvus Pharmaceuticals, Inc.Lead sponsor
- Corvus Pharmaceuticals, Inc.Study director
Drugs studied
Indications studied
- Squamous Cell Carcinoma of Head and Neck
- Urinary Bladder Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Uterine Cervical Neoplasms
- Lymphoma, Non-Hodgkin
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Sarcoma
- Colorectal Neoplasms
- Endometrial Neoplasms
- Prostatic Neoplasms, Castration-Resistant
- Triple Negative Breast Neoplasms
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.